Minerva Neurosciences Net Income
| NERV Stock | USD 6.31 0.66 11.68% |
As of the 10th of February, Minerva Neurosciences secures the Risk Adjusted Performance of 0.1288, downside deviation of 5.61, and Mean Deviation of 4.57. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Minerva Neurosciences, as well as the relationship between them. Please verify Minerva Neurosciences standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Minerva Neurosciences is priced some-what accurately, providing market reflects its recent price of 6.31 per share. Given that Minerva Neurosciences has jensen alpha of 0.8024, we recommend you to check Minerva Neurosciences's last-minute market performance to make sure the company can sustain itself at a future point.
Minerva Neurosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Minerva Neurosciences' valuation are provided below:Minerva Neurosciences does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. What growth prospects exist in Biotechnology sector? Can Minerva capture new markets? Factors like these will boost the valuation of Minerva Neurosciences. Anticipated expansion of Minerva directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each Minerva Neurosciences valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Understanding Minerva Neurosciences requires distinguishing between market price and book value, where the latter reflects Minerva's accounting equity. The concept of intrinsic value - what Minerva Neurosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Market sentiment, economic cycles, and investor behavior can push Minerva Neurosciences' price substantially above or below its fundamental value.
It's important to distinguish between Minerva Neurosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Minerva Neurosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Minerva Neurosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Minerva Neurosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Minerva Neurosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Minerva Neurosciences.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Minerva Neurosciences on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Minerva Neurosciences or generate 0.0% return on investment in Minerva Neurosciences over 90 days. Minerva Neurosciences is related to or competes with Klotho Neurosciences, Neurosense Therapeutics, Exicure, Neuraxis, Collplant Biotechnologies, TAO Synergies, and Rallybio Corp. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercializatio... More
Minerva Neurosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Minerva Neurosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Minerva Neurosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.61 | |||
| Information Ratio | 0.135 | |||
| Maximum Drawdown | 25.06 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 12.31 |
Minerva Neurosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Minerva Neurosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Minerva Neurosciences' standard deviation. In reality, there are many statistical measures that can use Minerva Neurosciences historical prices to predict the future Minerva Neurosciences' volatility.| Risk Adjusted Performance | 0.1288 | |||
| Jensen Alpha | 0.8024 | |||
| Total Risk Alpha | 0.2789 | |||
| Sortino Ratio | 0.1485 | |||
| Treynor Ratio | 0.6641 |
Minerva Neurosciences February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1288 | |||
| Market Risk Adjusted Performance | 0.6741 | |||
| Mean Deviation | 4.57 | |||
| Semi Deviation | 4.79 | |||
| Downside Deviation | 5.61 | |||
| Coefficient Of Variation | 666.65 | |||
| Standard Deviation | 6.18 | |||
| Variance | 38.14 | |||
| Information Ratio | 0.135 | |||
| Jensen Alpha | 0.8024 | |||
| Total Risk Alpha | 0.2789 | |||
| Sortino Ratio | 0.1485 | |||
| Treynor Ratio | 0.6641 | |||
| Maximum Drawdown | 25.06 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 12.31 | |||
| Downside Variance | 31.52 | |||
| Semi Variance | 22.99 | |||
| Expected Short fall | (5.08) | |||
| Skewness | 0.3665 | |||
| Kurtosis | 0.699 |
Minerva Neurosciences Backtested Returns
Minerva Neurosciences appears to be risky, given 3 months investment horizon. Minerva Neurosciences has Sharpe Ratio of 0.15, which conveys that the firm had a 0.15 % return per unit of risk over the last 3 months. By analyzing Minerva Neurosciences' technical indicators, you can evaluate if the expected return of 0.93% is justified by implied risk. Please exercise Minerva Neurosciences' Downside Deviation of 5.61, mean deviation of 4.57, and Risk Adjusted Performance of 0.1288 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Minerva Neurosciences holds a performance score of 11. The company secures a Beta (Market Risk) of 1.38, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Minerva Neurosciences will likely underperform. Please check Minerva Neurosciences' value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Minerva Neurosciences' current price movements will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Minerva Neurosciences has no correlation between past and present. Overlapping area represents the amount of predictability between Minerva Neurosciences time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Minerva Neurosciences price movement. The serial correlation of 0.0 indicates that just 0.0% of current Minerva Neurosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 0.25 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Minerva Neurosciences reported net income of 1.44 M. This is 99.58% lower than that of the Biotechnology sector and 97.95% lower than that of the Health Care industry. The net income for all United States stocks is 99.75% higher than that of the company.
Minerva Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Minerva Neurosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Minerva Neurosciences could also be used in its relative valuation, which is a method of valuing Minerva Neurosciences by comparing valuation metrics of similar companies.Minerva Neurosciences is currently under evaluation in net income category among its peers.
Minerva Fundamentals
| Return On Equity | -6.75 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 195.86 M | ||||
| Shares Outstanding | 6.99 M | ||||
| Shares Owned By Insiders | 22.25 % | ||||
| Shares Owned By Institutions | 28.26 % | ||||
| Number Of Shares Shorted | 321.38 K | ||||
| Price To Earning | 69.58 X | ||||
| Price To Book | 2.68 X | ||||
| Price To Sales | 1.87 X | ||||
| Gross Profit | (5.57 M) | ||||
| EBITDA | 6.02 M | ||||
| Net Income | 1.44 M | ||||
| Cash And Equivalents | 40.22 M | ||||
| Cash Per Share | 7.53 X | ||||
| Total Debt | 60 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 20.41 X | ||||
| Book Value Per Share | (4.95) X | ||||
| Cash Flow From Operations | (19.55 M) | ||||
| Short Ratio | 0.05 X | ||||
| Earnings Per Share | (1.85) X | ||||
| Target Price | 4.0 | ||||
| Beta | -0.42 | ||||
| Market Capitalization | 26.92 M | ||||
| Total Asset | 37.14 M | ||||
| Retained Earnings | (395.38 M) | ||||
| Working Capital | 19.43 M | ||||
| Current Asset | 33.48 M | ||||
| Current Liabilities | 5.32 M | ||||
| Net Asset | 37.14 M |
About Minerva Neurosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Minerva Neurosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Minerva Neurosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Minerva Neurosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Minerva Stock Analysis
When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.